Elutia (NASDAQ:ELUT) Posts Earnings Results, Beats Estimates By $0.11 EPS

Elutia (NASDAQ:ELUT) released its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.11, reports. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.00 million. Elutia had a negative return on equity of 407.37% and a net margin of 426.93%.

Here are the key takeaways from Elutia’s conference call:

• NXT-41x advanced toward regulatory review: Elutia said its key GLP animal study met predetermined endpoints, with no viable bacteria recovered from treated samples in the study. The company plans to submit the product to the FDA this quarter and expects a clearance decision around Q2 2027, subject to regulatory review.
• Elutia added $26 million in non-equity funding through an Avenue Capital loan, the SimpliDerm sale, and release of a Boston Scientific holdback. It ended the quarter with $29.1 million in cash, excluding the $8 million received on October 1, and management believes available funding can cover anticipated clearance and the first year of launch.
• The cardiovascular business grew 20% year over year to $1.1 million in Q3 revenue, with an 85.5% adjusted gross margin. Elutia is pursuing a sale to raise capital and sharpen its focus, but said it will not accept a deal that it considers unfavorable.
• Operating costs and losses increased: Q3 operating expenses rose to $7.6 million from $6.4 million, primarily due to higher R&D spending. Adjusted EBITDA loss widened to $5.6 million from $3.4 million; the prior-year net loss comparison was also affected by a $5.1 million non-cash warrant revaluation gain.

Elutia Trading Up 11.5%

NASDAQ:ELUT traded up $0.09 during midday trading on Friday, hitting $0.84. 85,106 shares of the company were exchanged, compared to its average volume of 101,229. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $1.39. The company has a market capitalization of $37.09 million, a PE ratio of 0.75 and a beta of 0.93. The company has a fifty day simple moving average of $0.82 and a 200 day simple moving average of $0.97.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Elutia from a “sell (d)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Elutia Company Profile

Elutia Inc is a medical technology company focused on developing and commercializing biologic products designed to support tissue healing and improve the performance of implantable medical devices. The company combines human tissue-based materials with drug-delivery and regenerative medicine technologies.

Its product portfolio includes biologic envelopes used to protect and support cardiac implantable electronic devices, including pacemakers and defibrillators. Elutia also develops tissue matrices and other biologic products for orthopedic, wound care and related surgical applications, with products intended to support soft-tissue repair, reconstruction and healing.

The company was formerly known as Aziyo Biologics and adopted the Elutia name as part of its broader focus on bioelectronic medicine and regenerative healthcare.